Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial cellular components affected by benzoyl peroxide-derived free radicals represent a broad set of molecular targets within Cutibacterium acnes (formerly Propionibacterium acnes), the primary bacterium associated with acne vulgaris (Matin & Goodman, 2023, StatPearls). These targets include bacterial proteins, lipids, and nucleic acids that are essential for the survival and replication of the organism (PubChem CID 2334). Benzoyl peroxide, a lipophilic oxidizing agent, penetrates the pilosebaceous unit and decomposes to release reactive oxygen species, specifically benzoyloxy and phenyl radicals (Kircik, 2013, J Drugs Dermatol). These radicals induce non-specific oxidative damage, such as lipid peroxidation of the cell membrane and the oxidation of protein sulfhydryl groups (Kawashima et al., 2017, J Dermatol). This widespread damage disrupts bacterial metabolism and structural integrity, resulting in a potent bactericidal effect. Because the drug targets multiple cellular components simultaneously, it is highly effective at reducing C. acnes populations. Furthermore, this non-specific mechanism of action significantly reduces the likelihood of bacteria developing resistance compared to traditional antibiotics. Consequently, these components are the primary therapeutic focus for topical benzoyl peroxide in the treatment of acne vulgaris.
Benzoyl peroxide acts as an oxidizing agent that releases free radicals (benzoyloxy and phenyl radicals) upon contact with the skin. These radicals cause non-specific oxidative damage to bacterial proteins, lipids, and DNA, leading to the death of Cutibacterium acnes (Matin & Goodman, 2023, StatPearls).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial cellular component (Cutibacterium acnes).